COVID-19 containment: China provides important lessons for global response

Abstract

The world must act fast to contain wider international spread of the epidemic of COVID-19 now. The unprecedented public health efforts in China have contained the spread of this new virus. Measures taken in China are currently proven to reduce human-to-human transmission successfully. We summarized the effective intervention and prevention measures in the fields of public health response, clinical management, and research development in China, which may provide vital lessons for the global response. It is really important to take collaborative actions now to save more lives from the pandemic of COVID-19.

Keywords

coronavirus disease 2019 (COVID-19) / control measure / public health response

References

[1] WHO. Coronavirus disease 2019 (covid-19) situation. report-47. March 7, 2020.

[2] The National Health Commission of the People’s Republic of China. Report on 2019- nCoV. March 8, 2020.

[3] WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020.

[4] The Health Commission of Wuhan. 41 COVID-19 patients were confirmed in Wuhan. January 11, 2020. (in Chinese)

[5] Hubei Provincial Government. Notice on Wuhan novel coronavirus infection of pneumonia epidemic prevention and control. January 23, 2020.(in Chinese)

[6] The Ministry of Finance and the National Health Commission of the People’s Republic of China. China issues 9.95b yuan additional funds for public health, epidemic control. January 28, 2020.

[7] The State Council of the People’s Republic of China. The notice on orderly resuming production and resuming production in enterprises. February 9, 2020. (in Chinese)

[8] The National Development and Reform Commission of the People’s Republic of China. China’s daily mask output exceeds 110 million units. March 7, 2020.

[9] Wang H, Wang Z, Dong Y, Chang R, Xu C, Yu X, Zhang S, Tsamlag L, Shang M, Huang J, Wang Y, Xu G, Shen T, Zhang X, Cai Y. Phase-adjusted estimation of the number of coronavirus disease 2019 cases in Wuhan, China. Cell Discov 2020; 6(1): 10

[10] Wuhan Municipal Government.Wuhan Huoshenshan Hospital was completed today. February 2, 2020.(in Chinese)

[11] Hubei Provincial Government. Wuhan Leishenshan Hospital welcomed its first confirmed 2019-nCoV patients. February 9, 2020. (in Chinese)

[12] The State Council. Press Conference of the joint Prevention and Control Mechanism of the State Council. March 6, 2020.(in Chinese)

[13] General Office of National Health Commission, General Office of National Administration of Traditional Chinese Medicine. Diagnostic and treatment protocol for novel coronavirus pneumonia (Trial version 7). March 4, 2020.(in Chinese)

[14] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020 Feb 3. [Epub ahead of print] doi: 10.1038/s41586-020-2012-7

[15] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727–733

[16] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565–574

[17] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506

[18] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JTK, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020 Jan 29. [Epub ahead of print] doi: 10.1056/NEJMoa2001316

[19] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020 Feb 24. [Epub ahead of print] doi: 10.1001/jama.2020.2648

[20] Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19(3): 149–150

[21] Tang B, Wang X, Li Q, Bragazzi NL, Tang S, Xiao Y, Wu J. Estimation of the transmission risk of the 2019-nCoV and its implication for public health interventions. J Clin Med 2020; 9(2): 462

[22] Li J, Wang Y, Gilmour S, . Estimation of the epidemic properties of the 2019 novel coronavirus: a mathematical modeling study. medRxiv 2020; doi: 10.1101/2020.02.18.20024315

[23] The Chinese Center for Disease Control and Prevention. China CDC publishes multilingual epidemic control manuals for COVID-19. March 2, 2020.

Acknowledgements

This work is funded by Medicine and Engineering Interdisciplinary Research Fund of Shanghai Jiao Tong University (No. YG2020YQ06), the National Key Research and Development Project (Nos. 2018YFC1705100 and 2018YFC1705103) and the National Natural Science Foundation of China (No. 71673187). We acknowledge all healthcare workers involved in the diagnosis and treatment of patients all around China. We thank National Health Commission of the People’s Republic of China for coordinating data collection for patients with COVID-19.

Compliance with ethics guidelines

Shuxian Zhang, Zezhou Wang, Ruijie Chang, Huwen Wang, Chen Xu, Xiaoyue Yu, Lhakpa Tsamlag, Yinqiao Dong, Hui Wang, and Yong Cai declare no conflicts of interest. This manuscript is a commentary and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

RIGHTS & PERMISSIONS

2020 Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature